EFFECTS OF LIRAGLUTIDE AND SEMAGLUTIDE DURING PREGNANCY
DOI:
https://doi.org/10.36557/2674-8169.2024v6n7p2485-2491Keywords:
Liraglutide, Semaglutide, Maternal and neonatal effects.Abstract
A search was carried out in the PubMed and Lilacs databases for studies that evaluated the maternal and neonatal consequences of the use of liraglutide and semaglutide during pregnancy. Observation of the studies revealed important variability in the findings, highlighting the need for more research to establish full principles on the safety of the use of semaglutide and liraglutide during pregnancy.
Downloads
References
Chao AM, Tronieri JS, Amaro A, Wadden TA. Semaglutide for the treatment of obesity. Trends Cardiovasc Med. 2023 Apr;33(3):159-166. doi: 10.1016/j.tcm.2021.12.008. Epub 2021 Dec 21. PMID: 34942372; PMCID: PMC9209591.
Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab. 2021 Apr;46:101102. doi: 10.1016/j.molmet.2020.101102. Epub 2020 Oct 14. PMID: 33068776; PMCID: PMC8085572.
Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, Lingvay I, Mosenzon O, Rosenstock J, Rubio MA, Rudofsky G, Tadayon S, Wadden TA, Dicker D; STEP 4 Investigators. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021 Apr 13;325(14):1414-1425. doi: 10.1001/jama.2021.3224. PMID: 33755728; PMCID: PMC7988425.
Tichy EM, Schumock GT, Hoffman JM, et al. National trends in prescription drug expenditures and projections for 2022. Am J Health Syst Pharm. 2022
Smits MM, Van Raalte DH. Safety of Semaglutide. Front Endocrinol (Lausanne). 2021 Jul 7;12:645563. doi: 10.3389/fendo.2021.645563. Erratum in: Front Endocrinol (Lausanne). 2021 Nov 10;12:786732. PMID: 34305810; PMCID: PMC8294388.
Agência Nacional de Vigilância Sanitária (ANVISA). Nota Técnica nº 60, de 17 de dezembro de 2010. Brasília, DF: ANVISA; 2010. Disponível em: https://bvsms.saude.gov.br/bvs/saudelegis/anvisa/2010/rdc0060_17_12_2010.p df. Acesso em: 15 jul. 2024.
Muller DRP, Stenvers DJ, Malekzadeh A, Holleman F, Painter RC, Siegelaar SE. Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence. Front Endocrinol (Lausanne). 2023 Oct 10;14:1215356. doi: 10.3389/fendo.2023.1215356. PMID: 37881498; PMCID: PMC10597691.
Chen C, Huang Y, Dong G, Zeng Y, Zhou Z. The effect of dipeptidyl peptidase-4 inhibitor and glucagon-like peptide-1 receptor agonist in gestational diabetes mellitus: a systematic review. Gynecol Endocrinol. 2020 May;36(5):375-380. doi: 10.1080/09513590.2019.1703943. Epub 2019 Dec 20. PMID: 31858859.
Minis E, Stanford FC, Mahalingaiah S. Glucagon-like peptide-1 receptor agonists and safety in the preconception period. Curr Opin Endocrinol Diabetes Obes. 2023 Dec 1;30(6):273-279. doi: 10.1097/MED.0000000000000835. Epub 2023 Sep 5. PMID: 37678163; PMCID: PMC10615799.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Alex Moreira Souza, Afonso Denofre de Carvalho, Aline Favero da Silva, Beatriz Colombo Molina, Brunna Silva Almeida, Caio Marcos Castaldeli Alves de Barros, Gustavo Lençone, Ingrid Condor Loureiro da Silva, Julia Tabile Casanova, Kleysson Handersson Arantes Souza de Campos, Leticia Jacomassi de Godoy, Renato Malavazi Galli
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors are copyright holders under a CCBY 4.0 license.
